Crizotinib (PF-02341066)

For research use only. Not for use in humans.

Pfizer辉瑞授权目录号：S1068

Crizotinib (PF-02341066) Chemical Structure

CAS No. 877399-52-5

Crizotinib (PF-02341066) 克唑替尼是一种有效的c-Met和ALK抑制剂，在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂，其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1812.55	现货
5mg	RMB 900.49	现货
10mg	RMB 1372.81	现货
50mg	RMB 4681.47	现货
200mg	RMB 11687.8	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Crizotinib (PF-02341066)发表文献306篇：

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cell, 2018, 174(4):856-869

PubMed: 30096312 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(6):681-690

PubMed: 28437395 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Cancer Discov, 2015, 10.1158/2159-8290.CD-15-0913

PubMed: 26566875 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Cancer Discov, 2014, 4(12):1398-405

PubMed: 25266736 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Nat Med, 2012, 18(6):883-91

PubMed: 22635005 ( click the link to review the publication )

Nat Med, 2011, 17(9):1116-20

PubMed: 21822287 ( click the link to review the publication )

Cancer Cell, 2011, 19(5):679-90

PubMed: 21575866 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)E372

PubMed: 33498427 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )
Nat Commun, 2020, 11(1):5704

PubMed: 33177525 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5017

PubMed: 33024122 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2853.2020

PubMed: 33310890 ( click the link to review the publication )

Dev Cell, 2020, 4;53(3):344-357 e5

PubMed: 32302545 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-3608

PubMed: 32034073 ( click the link to review the publication )

Clin Cancer Res, 2020, 8

PubMed: 32269053 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, canres.1992.2020

PubMed: 33203698 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2697

PubMed: 32967224 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):882

PubMed: 33082316 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Cancer Discov, 2020, 1 pii: CD-19-1030

PubMed: 32238360 ( click the link to review the publication )

Front Immunol, 2020, 11:527750

PubMed: 33324391 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1810-1821

PubMed: 33209603 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1904-1914

PubMed: 33209611 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3813-3823

PubMed: 32735723 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):403-423

PubMed: 32195017 ( click the link to review the publication )

Oral Oncol, 2020, 112:105074

PubMed: 33142224 ( click the link to review the publication )
Lung Cancer, 2020, 144:20-29

PubMed: 32353632 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29463

PubMed: 31960422 ( click the link to review the publication )

J Cell Sci, 2020, 11;133(9) pii: jcs241505

PubMed: 32184261 ( click the link to review the publication )

Antiviral Res, 2020, 178:104790

PubMed: 32272175 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Int J Biol Sci, 2020, 16(14):2595-2611

PubMed: 32792859 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015891

PubMed: 33087447 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00513-3

PubMed: 32918045 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Cancer Cell Int, 2020,

PubMed: 32874131 ( click the link to review the publication )

Oncol Rep, 2020, 43(3):817-826

PubMed: 32020234 ( click the link to review the publication )

Biomed Res Int, 2020, 2020:2046248

PubMed: 33376716 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Anticancer Res, 2020, 40(1):109-119

PubMed: 31892559 ( click the link to review the publication )

Anticancer Res, 2020, 40(3):1395-1403

PubMed: 32132036 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

NPJ Precis Oncol, 2020, 4:21

PubMed: 32802958 ( click the link to review the publication )

Hemasphere, 2020, 4(6):e497

PubMed: 33196013 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Oncogenesis, 2020, 9(7):64

PubMed: 32632141 ( click the link to review the publication )
Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3991

PubMed: 31488816 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4343

PubMed: 31554817 ( click the link to review the publication )

Clin Cancer Res, 2019, clincanres.1486.2019

PubMed: 31636099 ( click the link to review the publication )

EMBO Mol Med, 2019, 10.15252/emmm.201910581

PubMed: 31633304 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1667

PubMed: 31548343 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Cancer Res, 2019, 79(3):546-556

PubMed: 30538120 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Cancers (Basel), 2019,

PubMed: 31072019 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E104

PubMed: 30658414 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Cell Death Dis, 2019, 10(2):139

PubMed: 30760701 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(3):718-725

PubMed: 30755456 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31334113 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )
Biochem Pharmacol, 2019, 166:128-138

PubMed: 31078602 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480591 ( click the link to review the publication )

Sci Rep, 2019, 9(1):19353

PubMed: 31852910 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 383:114768

PubMed: 31639374 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1044

PubMed: 31690270 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):1231-1240

PubMed: 30653748 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 511(2):260-265

PubMed: 30791979 ( click the link to review the publication )

Future Oncol, 2019, 15(22):2585-2593

PubMed: 31339066 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31540894 ( click the link to review the publication )

Oncotarget, 2019, 10(65):6981-6996

PubMed: 31857852 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(10):1753-1765

PubMed: 31279006 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

J Clin Invest, 2018, 128(9):4086-4097

PubMed: 29990309 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3126-3136

PubMed: 29618618 ( click the link to review the publication )

Leukemia, 2018, 32(9):1994-2007

PubMed: 29588546 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cell Syst, 2018, 6(3):329-342

PubMed: 29550255 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(12):2732-2739

PubMed: 29559559 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):974

PubMed: 30250188 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):262

PubMed: 29449529 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2271-2284

PubMed: 30135214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):931-942

PubMed: 29440449 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):222-231

PubMed: 29054983 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

Front Oncol, 2018, 8:460

PubMed: 30464927 ( click the link to review the publication )

Sci Rep, 2018,

PubMed: 29849102 ( click the link to review the publication )

Cancer Gene Ther, 2018, 26(1-2):1-10

PubMed: 29925897 ( click the link to review the publication )

Cancer Discov, 2018, 8(6):714-729

PubMed: 29650534 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )

Cancer Res Treat, 2018, 50(2):599-613

PubMed: 28675026 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(2):251-263

PubMed: 29855693 ( click the link to review the publication )
Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5983-5991

PubMed: 30333869 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5992-5996

PubMed: 30333870 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Oncolytic Virother, 2018, 7:107-116

PubMed: 30538967 ( click the link to review the publication )

J Thorac Oncol, 2017, S1556-0864(17)30365-9

PubMed: 28502721 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3502-3512

PubMed: 28512244 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 28759046 ( click the link to review the publication )

Oncogene, 2017, 36(38):5407-5420

PubMed: 28534512 ( click the link to review the publication )

J Pathol, 2017, 243(3):307-319

PubMed: 28741662 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3013

PubMed: 28837150 ( click the link to review the publication )

Br J Cancer, 2017, 117(12):1787-1797

PubMed: 29024938 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

Oncologist, 2017, 22(2):158-164

PubMed: 28167572 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(2):203-217

PubMed: 28337371 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):191

PubMed: 28292264 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Molecules, 2017, 22(12)

PubMed: 29206199 ( click the link to review the publication )

Medchemcomm, 2017, 8(10):1914-1918

PubMed: 30108712 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )
Oncol Lett, 2017, 13(6):4085-4092

PubMed: 28599410 ( click the link to review the publication )

Cardiooncology, 2017, 3

PubMed: 28217366 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114945-114955

PubMed: 29383132 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51675-51687

PubMed: 28881678 ( click the link to review the publication )

Blood, 2016, 128(9):1234-45

PubMed: 27297792 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

J Clin Invest, 2016, 3;126(10):3739-3757

PubMed: 27571409 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(7):1787-99

PubMed: 26667487 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(22):5527-5538

PubMed: 27780853 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(24):6031-6038

PubMed: 27091406 ( click the link to review the publication )

Cancer Res, 2016,

PubMed: 27197184 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1506-16

PubMed: 26719536 ( click the link to review the publication )

Cancer Res, 2016, 76(4):974-83

PubMed: 26837769 ( click the link to review the publication )

J Pathol, 2016, 238(4):543-9

PubMed: 26606880 ( click the link to review the publication )

Cancer Discov, 2016, 6(12):1334-1341

PubMed: 27694386 ( click the link to review the publication )

Oncoimmunology, 2016, 5(3):e1094598

PubMed: 27141355 ( click the link to review the publication )

Oncoimmunology, 2016,

PubMed: 27141364 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2236-2244

PubMed: 27748834 ( click the link to review the publication )
Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Endocrine, 2016, 53(1):145-56

PubMed: 26370117 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2016, 77(3):623-8

PubMed: 26849637 ( click the link to review the publication )

PLoS One, 2016, 11(11):e0165983

PubMed: 27832137 ( click the link to review the publication )

Vet Parasitol, 2016, 227:64-8

PubMed: 27523939 ( click the link to review the publication )

Int J Surg, 2016, 28:179-84

PubMed: 26957017 ( click the link to review the publication )

World J Clin Oncol, 2016, 7(6):425-432

PubMed: 28008383 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep24817

PubMed: 27102549 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Springerplus, 2016, 5:348

PubMed: 27057482 ( click the link to review the publication )

Sci Rep, 2016, 6:32992

PubMed: 27623107 ( click the link to review the publication )

Tumour Biol, 2016, 37(4):4373-82

PubMed: 26499783 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75968-75980

PubMed: 27732954 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(17):23715-29

PubMed: 27009859 ( click the link to review the publication )

Blood, 2015, 126(26):2821-31

PubMed: 26531163 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-15-0370

PubMed: 25952648 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2916-27

PubMed: 26018086 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

PLoS Genet, 2015, 11(9):e1005533

PubMed: 26393505 ( click the link to review the publication )

Cancer Discov, 2015,

PubMed: 26432108 ( click the link to review the publication )
Oncoimmunology, 2015, 5(3):e1108514

PubMed: 27141364 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(11-:2433-40

PubMed: 26351321 ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Radiother Oncol, 2015,

PubMed: 25592111 ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Cancer Sci, 2015, 106(3):244-52

PubMed: 25581823 ( click the link to review the publication )

Lung Cancer, 2015, 90(3):590-7

PubMed: 26547802 ( click the link to review the publication )

J Cell Physiol, 2015, 230(9):2281-98

PubMed: 25704960 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 285(1):51-60

PubMed: 25841593 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1025-30

PubMed: 25502629 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0132330

PubMed: 26147305 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0124283

PubMed: 25919140 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0121378

PubMed: 25874976 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:375-83

PubMed: 25678804 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 10.1016/j.bbrc.2015.02.114

PubMed: 25735977 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015, 6(27):24320-32

PubMed: 26172300 ( click the link to review the publication )

Cell, 2015, 162(6):1271-85

PubMed: 26359985 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2015, 18(6):330-9

PubMed: 26104888 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26375439 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )

Oncotarget, 2015, 6(30):28774-89

PubMed: 26299615 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: 25144242 ( click the link to review the publication )
J Thorac Oncol, 2014, 9(11):1638-46

PubMed: ( click the link to review the publication )

J Thorac Oncol, 2014, 9(6):775-83

PubMed: 24828661 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(18):4806-15

PubMed: 25052479 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(44):E4706-15

PubMed: 25331893 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 10.7554/eLife.03751

PubMed: 25551293 ( click the link to review the publication )

Cancer Lett, 2014, 351(2):215-21

PubMed: 24887559 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(1):134-43

PubMed: 24170771 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0274

PubMed: 25349307 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Cancer Sci, 2014, 105(5):528-36

PubMed: 24612061 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: 25426675 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2014, 140(4):589-98

PubMed: 24509625 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2014, 74(5):1023-8

PubMed: 25205428 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:764981

PubMed: 25057499 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.10.126

PubMed: ( click the link to review the publication )

Jpn J Clin Oncol, 2014, 44(10):963-8

PubMed: 25170107 ( click the link to review the publication )

Future Oncol, 2014, 10(2):211-7

PubMed: 24490607 ( click the link to review the publication )
Leuk Res, 2014, 38(4):503-8

PubMed: 24486291 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014, 5(13):4920-8

PubMed: 24952482 ( click the link to review the publication )

Urol Oncol, 2014, 32(6):877-84

PubMed: 24929890 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):427-36

PubMed: 23335077 ( click the link to review the publication )

Int J Cancer, 2013, 132(2):E74-84

PubMed: 22948846 ( click the link to review the publication )

Br J Cancer, 2013, 109(12):3084-91

PubMed: 24149177 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

PLoS Genet, 2013, 9(11):e1003958

PubMed: 24278035 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1093-102

PubMed: 23993685 ( click the link to review the publication )

ACS Chem Biol, 2013, 9(3):777-84

PubMed: 24397822 ( click the link to review the publication )

J Am Heart Assoc, 2013, 2(6):e000376

PubMed: 24308935 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1640-6

PubMed: 24118504 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Sci Rep, 2013, 3:3450

PubMed: 24356251 ( click the link to review the publication )

Int J Cardiol, 2013, 168(4):3486-94

PubMed: 23680593 ( click the link to review the publication )

Mol Pharmacol, 2013, 83(4):882-93

PubMed: 23371912 ( click the link to review the publication )

Clin Chem Lab Med, 2013, 51(9):1843-8

PubMed: 23612660 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 272(1):245-55

PubMed: 23707608 ( click the link to review the publication )

J Cell Biochem, 2013, 114(4):816-22

PubMed: 23060267 ( click the link to review the publication )

Molecules, 2013, 18(12):15412-21

PubMed: 24335618 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )
PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56010

PubMed: 23418494 ( click the link to review the publication )

Oncotarget, 2013, 4(12):2237-48

PubMed: 24163262 ( click the link to review the publication )

Tumour Biol, 2013, 35(4):3229-35

PubMed: 24293393 ( click the link to review the publication )

Springerplus, 2013, 2:497

PubMed: 24102046 ( click the link to review the publication )

CELON PHARMA, 2013, 2013

PubMed: ( click the link to review the publication )

Sci Transl Med, 2012, 4(120):120ra17

PubMed: 22277784 ( click the link to review the publication )

Br J Pharmacol, 2012, 166(5):1669-83

PubMed: 22233293 ( click the link to review the publication )

Neoplasia, 2012, 14(7):572-84

PubMed: 22904675 ( click the link to review the publication )

ACS Chem Biol, 2012, 7(8):1429-35

PubMed: 22625864 ( click the link to review the publication )

J Biol Chem, 2012, 287(18):14586-97

PubMed: 22418436 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39812-23

PubMed: 23024367 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30820

PubMed: 22319590 ( click the link to review the publication )

Pediatr Blood Cancer, 2012, 17(23):7394-401

PubMed: 22488797 ( click the link to review the publication )

Clin Cancer Res, 2011, 59(3):440-7

PubMed: 21948233 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5255-64

PubMed: 21697284 ( click the link to review the publication )

J Biomol Screen, 2011, 16(2):141-54

PubMed: 21297102 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述

靶点

ROS1 ^[6] (Cell-free assay)	c-Met ^[1] (A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)	ALK ^[1] (Karpas299 cells)
<0.025 nM(Ki)	11 nM	24 nM

体外研究

PF-2341066作用于mIMCD3小鼠和MDCK犬上皮细胞，作用于c-Met磷酸化作用时具有相似效果，IC50分别为5 nM 和20 nM。PF-2341066作用于表达c-Met ATP-结合位点突变型V1092I 或H1094R或 P-环突变 M1250T 的NIH3T3 细胞，具有相似的活性，且活力增高，IC50分别为19 nM,2 nM 和15 nM,而作用于表达野生型受体的NIH3T3 细胞时，IC50为13 nM。^[1] 相反, 观察到PF-2341066作用于表达c-Met活化环突变型Y1230C 和Y1235D的细胞时，与作用于野生型受体相比，效果发生显著改变，IC50分别为127 nM 和92 nM。PF-2341066 作用于分别表达内源性c-Met 突变体R988C和 T1010I 的NCI-H69 和HOP92 细胞，也有效抑制c-Met 磷酸化, IC50分别为13 nM 和16 nM。与作用于c-Met相比，PF-2341066作用于VEGFR2 和PDGFRβ RTKs, 选择性高1000多倍，作用于IRK和Lck选择性高250多倍，作用于Tie2, TrkA,和TrkB选择性高40到60倍。PF-2341066 作用于RON和 Axl RTKs时选择性为20到30倍。相反，PF-2341066 作用于表达ALK RTK 的核磷蛋白 (NPM)- 间变性淋巴瘤激酶(ALK) 致癌融合突变体和 KARPAS299人间变性大细胞淋巴瘤(ALCL)细胞系时具有相近的IC50值，为24 nM。PF-2341066抑制c-Met依赖的癌细胞的肿瘤表现型，和内皮细胞的血管生成表现型。PF-2341066抑制人GTL-16胃癌细胞生长，IC50为9.7 nM。PF-2341066诱导 GTL-16细胞凋亡，IC50 为8.4 nM。PF-2341066 抑制HGF刺激的人NCI-H441肺癌细胞迁移和入侵，IC50分别为11 nM 和6.1 nM。PF-2341066抑制 MDCK细胞散射，IC50为16 nM。PF-2341066 抑制HGF-刺激的c-Met磷酸化,细胞存活，和Matrigel入侵，IC50分别为11 nM, 14 nM和35 nM。此外, PF-2341066抑制纤维蛋白胶中的血清刺激的 HMVEC分支小管形成 (形成血管)。^[1] PF-2341066 作用于Karpas299 或SU-DHL-1 ALCL细胞，也有效抑制 NPM-ALK磷酸化，IC50 为24 nM。PF-2341066 有效抑制细胞增殖，伴随着使细胞周期停在G(1)-S期，且诱导 ALK阳性的 ALCL 细胞凋亡，IC50为30 nM, 但是作用于ALK阴性的淋巴瘤细胞则无效果。 ^[2] 此外, PF-2341066 抑制骨肉瘤的一些活动行为，及其肿瘤生长 (例如,增殖和存活)和转移 (例如，入侵和形成克隆)。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
SU-DHL1	NYHNcox2S3m2b4TvfIlkKEG\|c3H5				NWnJWpB3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW1VvRFjMNUBk\WyuczDlfJBz\XO\|aX7nJGFNUyClb3X4dJJme3OrbnegUnBOKHerdHigTWM2OCCxZjCwMlAyKM7:TR?=	MoXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3N{K1PFkoRjJzNUeyOVg6RC:jPh?=
BAF3	M4XhRWN6fG:2b4jpZ{BCe3OjeR?=		NIDseI41QCCq	NX\tRpljTE2VTx?=	Moe4R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCwMlYzKM7:TR?=	M4L0WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUeyOVg6Lz5{MUW3NlU5QTxxYU6=
BAF3	NHP3VmZEgXSxdH;4bYMhSXO\|YYm=		NIXBOmw1QCCq	NUHVN\|ZqTE2VTx?=	MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIFyxNVk3VSCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR\|UxKG:oIEKuNkDPxE1?	M1;WWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUeyOVg6Lz5{MUW3NlU5QTxxYU6=
BAF3	NI[zOllEgXSxdH;4bYMhSXO\|YYm=		MVG0PEBp	Mn7HSG1UVw>?	NHPIdXlEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ\|IHPlcIx{KGW6cILld5NqdmdiRV3MOE1CVEtid3n0bEBKSzVyIH;mJFAvOjhizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV5MkW4PUc,OjF3N{K1PFk9N2F-
Kelly	NInp[mNEgXSxdH;4bYMhSXO\|YYm=			NVzxcI9VTE2VTx?=	MoHwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT4VtdHliY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCC5aYToJGlEPTBib3[gNE41OiEQvF2=	M1rlWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUeyOVg6Lz5{MUW3NlU5QTxxYU6=
SH-SY5Y	M1XIeGN6fG:2b4jpZ{BCe3OjeR?=			M3zHV2ROW09?	NGT6d4xEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy\|IHX4dJJme3OrbnegRWxMKEZzMUe0UEBufXSjboSge4l1cCCLQ{WwJI9nKDBwNUOg{txO	NUDic\|lmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1O\|I2QDlpPkKxOVczPTh7PD;hQi=>
SMS-KCN	MVLDfZRwfG:6aXOgRZN{[Xl?			M4L0NWROW09?	NWLmNJZJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW02VLVvDUkBk\WyuczDlfJBz\XO\|aX7nJGFNUyCUMUK3OXEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkmxJO69VQ>?	Mm\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3N{K1PFkoRjJzNUeyOVg6RC:jPh?=
BAF3	NGjMS41EgXSxdH;4bYMhSXO\|YYm=		MoP3OFghcA>?	M17LOmROW09?	MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochXGWuLVHMT{B4cXSqIFnDOVAhd2ZiMD6xPUDPxE1?	MofyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3N{K1PFkoRjJzNUeyOVg6RC:jPh?=
3T3	NWjyNVBCTnWwY4Tpc44hSXO\|YYm=		M3G3WVEhcA>?	NESyfmJFVVOR	MWLJcohq[mm2aX;uJI9nKFKRTjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yODFOwG0>	Ml\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MUK0NVQoRjJzOEGyOFE1RC:jPh?=
3T3-E	M{fZV2Z2dmO2aX;uJGF{e2G7		NVv6Rpo3OSCq	MnrKSG1UVw>?	M{G4fWlvcGmkaYTpc44hd2ZiVFnFNkBie3Onc4Pl[EBoem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC52NEig{txO	Mn;5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MUK0NVQoRjJzOEGyOFE1RC:jPh?=
A549	MWHLbY5ie2ViQYPzZZk>		MnHVNUBp	NIj0UmpFVVOR	M1\iemlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiYz3NSXQhc2mwYYPlJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGhITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB6IN88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzMkSxOEc,OjF6MUK0NVQ9N2F-
BAF3-BCL	NXG1TmJuTnWwY4Tpc44hSXO\|YYm=		MlPyNUBp	MoLQSG1UVw>?	NETKWFBKdmirYnn0bY9vKG:oIFHCUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMT6xOVkh\|ryP	Ml;WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MUK0NVQoRjJzOEGyOFE1RC:jPh?=
HEK293	NX7LWWF[TnWwY4Tpc44hSXO\|YYm=		NGXYO\|EyKGh?	MYfEUXNQ	NITRZnpKdmirYnn0bY9vKG:oIFHYUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6yPVQh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzMkSxOEc,OjF6MUK0NVQ9N2F-
HEK293	NFLrfmtHfW6ldHnvckBCe3OjeR?=		NVXLOGJJOSCq	NYHBO4RlTE2VTx?=	NHexZZRKdmirYnn0bY9vKG:oIFnSJIF{e2W\|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lki4O{DPxE1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzMkSxOEc,OjF6MUK0NVQ9N2F-
Jurkat	NXXTT2p5TnWwY4Tpc44hSXO\|YYm=		M2\I[FEhcA>?	MWPEUXNQ	NH\QSYJKdmirYnn0bY9vKG:oIFzDT{Bie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj63OFEh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzMkSxOEc,OjF6MUK0NVQ9N2F-
KARPAS299	M1T6cGtqdmG\|ZTDBd5NigQ>?		MV[xJIg>	NEjHbmJFVVOR	NHuzNJFKdmirYnn0bY9vKG:oIFHMT{Bie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNkDPxE1?	NXzYV4tLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NVI1OTRpPkKxPFEzPDF2PD;hQi=>
PAE	MWPGeY5kfGmxbjDBd5NigQ>?		MV2xJIg>	MVLEUXNQ	NFnFN2RKdmirYnn0bY9vKG:oIGTST2Ih[XO\|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuN\|k6KM7:TR?=	MkSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MUK0NVQoRjJzOEGyOFE1RC:jPh?=
PAE	MYfGeY5kfGmxbjDBd5NigQ>?		NHPNVGUyKGh?	M37WTmROW09?	MmrZTY5pcWKrdHnvckBw\iCWUlvBJIF{e2W\|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkW4JO69VQ>?	M13tTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEGyOFE1Lz5{MUixNlQyPDxxYU6=
BAF3	MWnGeY5kfGmxbjDBd5NigQ>?		NF\QNYwzNTNiZB?=	MVfEUXNQ	NGTSN4dKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDpcpN2dGmwIILlZ4VxfG:{IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOS54NEOg{txO	Mo\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NEKyOVIoRjJ\|N{SyNlUzRC:jPh?=
BAF3	MlSwSpVv[3Srb36gRZN{[Xl?		M33zNFIuOyCm	NWPKeIxGTE2VTx?=	M4\OUWlvcGmkaYTpc44hd2ZiTmDNMYZ2e2WmIFHMT{ApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSUZ\|IHPlcIx{KGGodHXyJFIhfG9iMzDkZZl{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUB4cXSqIFnDOVAhd2ZiMD6xOVA5KM7:TR?=	NX;sS2xJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFIzPTJpPkKzO\|QzOjV{PD;hQi=>
BAF3	MVLGeY5kfGmxbjDBd5NigQ>?		NVvTdJl3Oi1\|IHS=	MXzEUXNQ	NYnJPIpyS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCjZoTldkAzKHSxIEOg[IF6eyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZkhf2m2aDDJR\|UxKG:oIEOuOFc6KM7:TR?=	M{LmSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{SyNlUzLz5{M{e0NlI2OjxxYU6=
KARPAS299	MVzDfZRwfG:6aXOgRZN{[Xl?		NH:2[pczNTNiZB?=	NYT6fFdpTE2VTx?=	MVHJR\|UxRTBwME[0NkDPxE1?	MoDZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NEKyOVIoRjJ\|N{SyNlUzRC:jPh?=
EBC1	M{DQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVi3NkBp	MYHEUXNQ	M3r1bWlEPTB;MD6wNlMh\|ryP	NIHw[ZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m5N\|MzQCd-MkO5PVM{Ojh:L3G+
HCT116	NHPpPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV7yd3l6PzJiaB?=	NVTqcGNLTE2VTx?=	NGTVeJhKSzVyPUG0MlgzKM7:TR?=	NYLtfnVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
MCF7	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXu3NkBp	NYDZPHdITE2VTx?=	M363UGlEPTB;OT61PEDPxE1?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl7M{OyPEc,OjN7OUOzNlg9N2F-
MDA-MB-231	NIHtTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV\ITHVSPzJiaB?=	NVTzNJZNTE2VTx?=	NULTeIdXUUN3ME2xNE45KM7:TR?=	M3\wfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUmzN\|I5Lz5{M{m5N\|MzQDxxYU6=
MKN45	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2LNTlczKGh?	MUnEUXNQ	NUjMTo1MUUN3ME2wMlAyOyEQvF2=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl7M{OyPEc,OjN7OUOzNlg9N2F-
NCI-H441	M4PlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn7sO\|IhcA>?	M1XzOmROW09?	MonUTWM2OD1zNz6yOUDPxE1?	NWPC[nJnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
NCI-H661	M2fCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH;mTWk4OiCq	MWrEUXNQ	NUPIOIlpUUN3ME2xNU41PyEQvF2=	NX7ISYxLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
SK-MEL-28	NXLN[XRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX3NdFR[PzJiaB?=	NYniT2FETE2VTx?=	MonYTWM2OD1zMD65O{DPxE1?	M2f1Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUmzN\|I5Lz5{M{m5N\|MzQDxxYU6=
SKOV3	MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXzETHNHPzJiaB?=	NY\qeJczTE2VTx?=	MVfJR\|UxRTF{Lki1JO69VQ>?	NU\WZ5h2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
SNU5	M1rHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml;EO\|IhcA>?	NXvUUWFPTE2VTx?=	MlznTWM2OD1yLkCxOkDPxE1?	NIHOc4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m5N\|MzQCd-MkO5PVM{Ojh:L3G+
Antiproliferative assay	NGLJPGVGSkNz		NF3pSJU4OiCqcoO=		MoTaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCHQlOxJINmdGy\|IHX4dJJme3Orbneg[YxmfmG2ZXSgcIV3\Wy\|IH;mJINwdnO2aYT1eIl3\Wy7IHHjeIl3\SClLV3leEBi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE4xPTNizszNMi=>	M4K4O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OE[zOVI6Lz5{Mki2N\|UzQTxxYU6=
Function assay	Mn35T2FTWEGVMkm5		MU[3NkBpenN?		MYHJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCNQWLQRXMzQTliY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldkBIdG9iYYPzZZktKEmFNUCgQUAxNjB4MjFOwG0v	NX7PXm03RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N\|I6ODlpPkK0OFMzQTB7PD;hQi=>
Function assay	M13PdG5KUC1\|VEO=		NUXYcoRuOSCqch?=		M{nYSGlvcGmkaYTpc44hd2ZiaIXtZY4hf2muZDD0fZBmKEWPTESt[pV{\WRiQVzLJIV5eHKnc4Pl[EBqdiCvb4Xz[UBPUUhvM2SzJINmdGy\|IHHzd4V{e2WmIHHzJJBpd3OyaH;yfYxifGWmIFHMT{Bt\X[nbDDh[pRmeiBzIHjyJIJ6KHOjbnT3bYNpKEWOSWPBMEBKSzVyIE2gNE4xQCEQvF2u	NEC2RlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N\|I6ODl:L3G+
Function assay	NGPMcpVPS0lvSEOxNlI>		MUC3NkBpenN?		NEfXS5NKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmeiCJbH:gZZN{[XluIFnDOVAhRSByLkGwPEDPxE1w	NXXabFFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N\|I6ODlpPkK0OFMzQTB7PD;hQi=>
Function assay	MXzOR2kuUDJ{Mki=		NHrubVc4OiCqcoO=		M3;tVWlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIHnuJIh2dWGwIF7DTU1JOjJ{ODDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzKEeubzDhd5NigSxiSVO1NEA:KDBwMUG4JO69VS5?	NEWycIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N\|I6ODl:L3G+
Function assay	NIX1TYJPUUhvM2Sz		NWKzToVWOSCqch?=		Mn[4TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDGNVE4PExibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkG2OUDPxE1w	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR\|MkmwPUc,OjR2M{K5NFk9N2F-
Function assay	M4jBTm5KUC1\|VEO=		M{PHXlEhcHJ?		MmKyTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDDNVE2PllibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkS3PEDPxE1w	MoSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay	NFfpbllPUUhvM2Sz		MojZNUBpeg>?		NXzEVIxYUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJ4OVGgcZV1[W62IHX4dJJme3OnZDDpckBud3W\|ZTDOTWguO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlYxPSEQvF2u	MkGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay	NIT0UJdPS0lvSEOxNlI>		M{DtcVczKGi{cx?=		M1zUUGlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIHnuJIh2dWGwIF7DTU1JOzF{MjDj[YxteyCqYYLic5JqdmdiQVzLJGcyOjZ7QTDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmeiCJbH:gZZN{[XluIFnDOVAhRSByLk[yN{DPxE1w	M3XDRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEOyPVA6Lz5{NESzNlkxQTxxYU6=
Function assay	NYq4VGdTVkmKLUPUNy=>		NYLy[HkxOSCqch?=		M2LwcGlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugV\|EzOD[\IH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViTlnIMVNVOyClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwNUGOSzDs[ZZmdCCjZoTldkAyKGi{IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMD62NlYh\|ryPLh?=	NYDjbVR2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N\|I6ODlpPkK0OFMzQTB7PD;hQi=>
Function assay	M4TZZm5EUS2KM{GyNi=>		MmH2O\|IhcHK\|		MV3Jcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIhT2yxIHHzd4F6NCCLQ{WwJF0hOC56M{ig{txONg>?	NIqzOGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N\|I6ODl:L3G+
Function assay	MYPOTWguO1R\|		M4jxSFEhcHJ?		NXr6UnJxUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF7Nl2gcZV1[W62IHX4dJJme3OnZDDpckBud3W\|ZTDOTWguO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlg1OyEQvF2u	NGri[2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N\|I6ODl:L3G+
Function assay	NUPDS3pRVkmKLUPUNy=>		MXuxJIhz		NUH1cpY2UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF3MmKgcZV1[W62IHX4dJJme3OnZDDpckBud3W\|ZTDOTWguO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCxMlAzPiEQvF2u	MmTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay	NUX2OWcxVkmKLUPUNy=>		NVTwR3o{OSCqch?=		NEPZO2RKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJFEyPTGWaX7zJI12fGGwdDDlfJBz\XO\|ZXSgbY4hdW:3c3WgUmlJNTOWMzDj[YxteyCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDDh[pRmeiBzIHjyJIJ6KHOjbnT3bYNpKEWOSWPBMEBKSzVyIE2gN{4xOzlizszNMi=>	MnfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay	NUPDVJRYSkGIMx?=		M2PlTVczKGi{cx?=		Mo\jTY5pcWKrdHnvckBw\iCQUF2vRWxMKCi3bnvuc5dvKG:{aXfpckkhfHKjboPm[YN1\WRiaX6gcY92e2ViQlHGN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCdM1jdMZRpgW2rZHnu[UBqdmOxcoDvdoF1cW:wIHHzd4F6NCCLQ{WwJF0hOC5yNUGg{txONg>?	M2qwT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NE[4OlMzLz5{NES2PFY{OjxxYU6=
Function assay	Mm\3RmFHOw>?		MlvvO\|IhcHK\|		M2[4bmlvcGmkaYTpc44hd2ZiTmDNM2FNUyBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliW{PIYU11cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NEA:KDBwMEWxJO69VS5?	NXK4UlNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0Olg3OzJpPkK0OFY5PjN{PD;hQi=>
Function assay	MnziRmFHOw>?		MofpO\|IhcHK\|		NFjCT3JKdmirYnn0bY9vKG:oIF7QUU9CVEtiTEGxPVZOKG23dHHueEApfW6tbn;3ckBwemmpaX6pJJRz[W6\|ZnXjeIVlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhYzOKXT30bJlucWSrbnWgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MDC9JFAvOjZizszNMi=>	NIHr[pY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES2PFY{Oid-MkS0Olg3OzJ:L3G+
Cytotoxicity assay	MV7CRWY{		NYjEVmpPPzJiaILz		MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBcO0ifLYTofY1q\GmwZTDpcoNwenCxcnH0bY9vKGG\|c3H5MEBKSzVyIE2gNE46QCEQvF2u	NWmzPHpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0Olg3OzJpPkK0OFY5PjN{PD;hQi=>
Antiproliferative assay	NF[xSIlPUUhxM2Sz		NH[wTGE4OiCqcoO=		M4m2eWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgZ5Jqgm:2aX7pZk1z\XOrc4ThcpQhdW:3c3WgUmlJNzOWMzDj[YxteyCqYYLic5JqdmdiRV3MOE1CVEtidnHybYFvfCBzIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC5OVQh\|ryPLh?=	NE\o[Zo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OVQ3PSd-MkS3PFU1PjV:L3G+
Antiproliferative assay	MoT5V3VRNU1{		NXvDSnVbPzJiaILz		NFHs[YlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPVVE1OOiClZXzsd{Bp[XKkb4LpcochVlCPLVHMT{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yPzRizszNMi=>	NHjMOYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OVQ3PSd-MkS3PFU1PjV:L3G+
Antiproliferative assay	NVXINW1FVkmKL{PUNy=>		MYS3NkBpenN?		NECzR5pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JINzcXqxdHnubYIuemW\|aYP0ZY51KG2xdYPlJG5KUC9\|VEOgZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNII\hdolidnRiMT;MNVE6Pk1ibYX0ZY51KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjZyNjFOwG0v	NHmyTHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OVQ3PSd-MkS3PFU1PjV:L3G+
Function assay	MYTOTWguO1R\|		NH\Rc4oyKGi{		MYPJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCqdX3hckBGVUx2LX\1d4VlKEGOSzDlfJBz\XO\|ZXSgbY4hdW:3c3WgUmlJNTOWMzDj[YxteyCjc4Pld5Nm\CCjczDwbI9{eGixconsZZRm\CCDTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuNFgh\|ryPLh?=	NEPuUJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixPVEyPid-MkS4NVkyOTZ:L3G+
Function assay	NWfFcmRoVkmKLUPUNy=>		MYSxJIhz		NHrvfZRKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGYyOTd2TDDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuNVY2KM7:TT6=	NVPrUYZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
Function assay	MYXOTWguO1R\|		NEjGSI4yKGi{		MUjJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFOxNVU3YSCvdYThcpQh\XiycnXzd4VlKGmwIH3veZNmKE6LSD2zWFMh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywh[W[2ZYKgNUBpeiCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDBwNEe4JO69VS5?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhzOUGxOkc,OjR6MUmxNVY9N2F-
Function assay	NVn1U2x3VkmKLUPUNy=>		NIfyOpQyKGi{		M4jDZ2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugS\|EzPjmDIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViTlnIMVNVOyClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwNUGOSzDs[ZZmdCCjZoTldkAyKGi{IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMD62NFUh\|ryPLh?=	NGfWdXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixPVEyPid-MkS4NVkyOTZ:L3G+
Function assay	NWXVOWg6VkmKLUPUNy=>		NHX6[3AyKGi{		NFLRV2xKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJHMyOjB4WTDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuOlI3KM7:TT6=	Mki4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUmxNVYoRjJ2OEG5NVE3RC:jPh?=
Function assay	M3n2Zm5KUC1\|VEO=		NHHVc3YyKGi{		NEO1U29KdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTl4TTDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuPFQ{KM7:TT6=	NI\MN\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixPVEyPid-MkS4NVkyOTZ:L3G+
Function assay	Ml;XUmlJNTOWMx?=		M3fH[\|EhcHJ?		NFTuXnNKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTV{UjDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IEGuNFI3KM7:TT6=	NEnMfYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixPVEyPid-MkS4NVkyOTZ:L3G+
Function assay	M{m1c25KUC1\|VEO=		NEntNVcyKGi{		NHTPSmZKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjB{UjDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IEGuNVQ5KM7:TT6=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhzOUGxOkc,OjR6MUmxNVY9N2F-
Function assay	NInz[nhPUUhvM2Sz		NXjjSXJIOSCqch?=		NXe0UZJQUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{AyOTVzVHnud{BufXSjboSg[ZhxemW\|c3XkJIlvKG2xdYPlJG5KUC1\|VEOgZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXygZYZ1\XJiMTDodkBjgSC\|YX7ke4lkcCCHTFnTRUwhUUN3MDC9JFMvODN7IN88UU4>	M3L3dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG5NVE3Lz5{NEixPVEyPjxxYU6=
Function assay	MWPNT245PDV?		MXqxJIhz		NXXvS4o3UW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hVUuQOES1JINmdGy\|IHHmeIVzKDFiaIKgZpkhf2W\|dHXyckBjdG:2dHnu[{whUUN3MDC9JFAvODJizszNMi=>	NFn1bGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFc2OCd-MkS5NFA4PTB:L3G+
Function assay	MnTsUWtPQDR3		MmC3PVAhdWmwcx?=		NVHoNYl2UW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hVUuQOES1JINmdGy\|IHHmeIVzKDlyIH3pcpMh[nliU3Hu[Jdq[2hvRVzJV2EtKEmFNUCgQUAxNjB{IN88UU4>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEe1NEc,OjR7MEC3OVA9N2F-
Function assay	MYnrZZJx[XNiMkm5		Mn2wPVAhdWmwcx?=		M2TUWmlvcGmkaYTpc44hd2ZiTmDNMYZ2e2WmIFHMT{BxcG:\|cHjvdplt[XSrb36gLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hcHWvYX6gb4FzeGG\|IEK5PUBk\WyuczDh[pRmeiB7MDDtbY5{KGK7IGPhcoR4cWOqLVXMTXNCNCCLQ{WwJF0hOC5zMTFOwG0v	NV7reYpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4PTBpPkK0PVAxPzVyPD;hQi=>
Cytotoxicity assay	MVrOR2kuUDF7OUO=		NWGxOJR2PDhiaILz		MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7OUOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwME[xJO69VS5?	M2fIeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwPFMxLz5{NEmwNFg{ODxxYU6=
Cytotoxicity assay	NFTsSmJPUUhxM2Sz		MXS0PEBpenN?		M4L3cWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJG5KUC9\|VEOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwM{[0JO69VS5?	NFLDOo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OCd-MkS5NFA5OzB:L3G+
Cytotoxicity assay	MUTBOVQ6		NUnJdYdmPDhiaILz		M2fKb2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFQvODh2IN88UU4>	MmG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N\|AoRjJ2OUCwPFMxRC:jPh?=
Cytotoxicity assay	NFnZZ5pPS0lvSEG5O\|U>		MYK0PEBpenN?		M33wfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUm3OUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNz61OVEh\|ryPLh?=	NIrp[Zc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OCd-MkS5NFA5OzB:L3G+
Antiproliferative assay	MVrFRmMy		MY[3NkBpenN?		NGDkXFBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JINOTVRvYX3wcIlncWWmIHj1cYFvKEWEQ{GgZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNE4xODZ7IN88UU4>	M13k[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwPFMyLz5{NEmwNFg{OTxxYU6=
Antiproliferative assay	NVzWXYdkU0GUUFHTNlk6		M1L2XVczKGi{cx?=		NULObmtDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBCVEtvZHXw[Y5l\W62IHj1cYFvKEuDUmDBV\|I6QSClZXzsd{Bi\nSncjC3NkBpenNuIFnDOVAhRSByLkKg{txONg>?	MlHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N\|EoRjJ2OUCwPFMyRC:jPh?=
Antitumor assay	M3S0NmJCTjN?	MX61NEBu\y:tZx?=	MnS1NkB4\WWtcx?=		NHLJeVBCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGsh\nW\|aX;uJJBzd3SnaX6gZYxtd2e{YX\0[YQhcW5iboXk[UBud3W\|ZTDhd5Nme3OnZDDhd{B1fW2xcjDndo94fGhiaX7obYJqfGmxbjDheEA2OCCvZz;r[{wheG9icXSg[o9zKDJid3Xlb5MhemWuYYTpeoUhfG9idnXobYNt\S22cnXheIVlKGOxboTyc4w>	MonRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N\|EoRjJ2OUCwPFMyRC:jPh?=
Antiproliferative assay	NX3yRWN3TUKFMR?=		MmW0O\|IhcHK\|		NGS5TGFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFXCR\|Eh[2WubIOgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC5yMkGg{txONg>?	NWXWW4FyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|c2OzBpPkK1OVM4PTNyPD;hQi=>
Antiproliferative assay	M3uzcXNPXTV?		NXywToZLPzJiaILz		MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOQVUWgZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNE4xOjB2IN88UU4>	NYjpRZFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFU2OjNpPkK2NFA2PTJ\|PD;hQi=>
Antiproliferative assay	MkXWSWJEOQ>?		NIHld3M4OiCqcoO=		NI\2T3dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFXCR\|Eh[2WubIOgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC5yMkG4JO69VS5?	NFnROWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOVUzOyd-Mk[wNFU2OjN:L3G+
Antiproliferative assay	MXfNT241PQ>?		NIf5UFU4OiCqcoO=		NHi1[GdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3LUlQ2KGOnbHzzJIFnfGW{IEeyJIhzeyxiSVO1NEA:KDBwMEO4NUDPxE1w	M{L2TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC1OVI{Lz5{NkCwOVUzOzxxYU6=
Antiproliferative assay	MnXSRmFHOy:WUGKtUYV1		NUToPXljPzJiaILz		NXrTelVjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{N1SSUj3N[ZQh[2WubIOgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC5zMke0JO69VS5?	NVPrOGhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFU2OjNpPkK2NFA2PTJ\|PD;hQi=>
Antiproliferative assay	MVLOR2kuUDNzMkK=		NUjGcIZ5PzJiaILz		MnnwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDBUGsu\GWyZX7k[Y51KGi3bXHuJG5EUS2KM{GyNkBk\WyuczDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjJ4MUKg{txONg>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5Nke0PUc,OjZ2N{[3OFk9N2F-
Antiproliferative assay	MlTQUmNKNUh\|MUKy		NVLmbpNRPzJiaILz		M4fweGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIFz1cYlv\XOlZX70JGNmdGxiVnnhZoltcXS7IFHzd4F6NCCHQ{WwJF0hOC5yM{Kg{txONg>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay	M{fCTWJiN0Z\|		MWe3NkBpenN?		MUPJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0MWFNUyBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMD6wOVYh\|ryPLh?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay	NHPreWVD[S:IMx?=		NILDR5A4OiCqcoO=		NHPWcHpKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1NUGOSzCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCZU9HOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNE4xPTZizszNMi=>	NVXZeI9ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Function assay	NHfoSZpD[S:IMx?=		MUS3NkBpenN?		NYfLTYVvUW6qaXLpeIlwdiCxZjDFUWw1NUGOSzDTNVIxPllibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKjL1[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkC2OUDPxE1w	M2DuRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Function assay	M1fNUmJiN0Z\|		NWXablZ1PzJiaILz		MmfqTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCIMUG3OGwhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAxNjB6MTFOwG0v	MkLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Function assay	M3OwWmJiN0Z\|		MomzO\|IhcHK\|		Ml\PTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCFMUG1OnkhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAxNjF2NDFOwG0v	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Antiproliferative assay	MmTIV21UNUuFTmK=		NXPnflhvPzJiaILz		NIS1ZZJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPNV{1MS06UIHPlcIx{KGW6cILld5NqdmdiRV3MOE1CVEtiUkGyO\|VSKG23dHHueEBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCOdX3pcoV{[2WwdDDD[YxtKF[rYXLpcIl1gSCDc4PhfUwhTUN3MDC9JFAvOTd7IN88UU4>	MlzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay	NUD3dmR6U2WubIm=		MlHHO\|IhcHK\|		M1LvNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS3XscJkh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BHOTF5NFygcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD6yNVEh\|ryPLh?=	NVTPZm0{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Antiproliferative assay	MnXwUGFPPQ>?		MoHhO\|IhcHK\|		NUfCV4U6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMRW42KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshWjF{N{XRJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuNlMzKM7:TT6=	NEnFXHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	NH;NfHBFTkOLN{[=		Mon5O\|IhcHK\|		M3PJdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRF\DTVc3KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshVDFzNULSJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuNlM{KM7:TT6=	M4r3TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Function assay	MmjIRoEwTjN?		M4fUU\|czKGi{cx?=		M{K0emlvcGmkaYTpc44hd2ZiRV3MOE1CVEtiR{GyNFJTKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC5\|Mkig{txONg>?	Mn:zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay	MmHkV2suVi2VSB?=		Mn7DO\|IhcHK\|		M1LJc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1UUCClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKEZzMUe0UEBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hVHWvaX7ld4NmdnRiQ3XscEBXcWGkaXzpeJkhSXO\|YYmsJGVEPTBiPTCwMlM4KM7:TT6=	NV;a[plRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Antiproliferative assay	M1r6c2NJVEF{MB?=		NIrYPYw4OiCqcoO=		Mk\NRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFSFzBNlAh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BTOTJ5NWGgcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD60N\|kh\|ryPLh?=	NVPLUGVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Function assay	Mn7rRoEwTjN?		NF;r[Fc4OiCqcoO=		MorrTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCJMUK2PWEhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAxNjVzMjFOwG0v	M3f0[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay	M3HpZXNJNVO\NWm=		NXPwSmVqPzJiaILz		MlK4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVSD3TXVV[KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshTjFzN{TMJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuOVI{KM7:TT6=	MnvXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Function assay	MoG2RoEwTjN?		NWPKVG5nPzJiaILz		NWTPSXlTUW6qaXLpeIlwdiCxZjDFUWw1NUGOSzDMNVE6Pk1ibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKjL1[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkW0PUDPxE1w	NXvIVYJyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Function assay	NVHMfIVRSmFxRkO=		MmnFO\|IhcHK\|		NV3DUodsUW6qaXLpeIlwdiCxZjDFUWw1NUGOSzDMNVE2OlJibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKjL1[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLk[0OUDPxE1w	M2fkT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay	NYPKOZJ{W0tvTj3CSUgzMQ>?		NXPa[IZZPzJiaILz		M3:3U2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1DTSh{KTDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDFUWw1NUGOSzDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuO\|Eh\|ryPLh?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay	MVTCZU9HOw>?		NFrXb\|U4OiCqcoO=		NFnGUWlKdmirYnn0bY9vKG:oIFXNUFQuSUyNIEGxOVFVcW6\|IH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMD64OVch\|ryPLh?=	M3H6OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Cytotoxicity assay	M{\BfGJCN0Z\|		M165OVczKGi{cx?=		M3\YXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAxNjl{NzFOwG0v	NHe0NGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	NGjDfmRNSU5z		M33RUVczKGi{cx?=		NX65TVJvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMRW4yKGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshTjFzN{TMJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IEGuN\|Q3KM7:TT6=	NEWwS4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	NF[2Z5NUUy2QLV\J		MmK1O\|IhcHK\|		MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV6tSmkh[2WubIOg[ZhxemW\|c3nu[{B4cWymIIT5dIUhTU2OND3BUGsh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iTIXtbY5me2OnboSgR4VtdCCYaXHibYxqfHliQYPzZZktKEWFNUCgQUAyNjR4OTFOwG0v	M3fHOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay	M1\FNXNMNU5vQWO=		NHPtWmQ4OiCqcoO=		NYfKfmprSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNUGVIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMT60O\|Mh\|ryPLh?=	Mli5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay	M{G3U2RHS0lzMUS=		MkfRO\|IhcHK\|		MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESIQ1mxNVQh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BIOTJ4OVGgcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMT62NVUh\|ryPLh?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Antiproliferative assay	NYPtR5pJTUKFMR?=		MkDlO\|IhcHK\|		NX62cHIySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlAyQSEQvF2u	Mk\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4OUi1N\|YoRjJ4Nkm4OVM3RC:jPh?=
Cytotoxicity assay	MVHFRmMy		NX7INmx1PzJiaILz		NFP5NIhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBGSkNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR\|UxKD1iMD6wOFQh\|ryPLh?=	NGnwNnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CxO\|U1QCd-MkewNVc2PDh:L3G+
Antiproliferative assay	MULLRXJRSVN{OUm=		NYT4eFhWPzJiaILz		MlPBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNQWLQRXMzQTliY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSi:FQ1utPEBie3OjeTygTWM2OCB;IECuNVA{KM7:TT6=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MUC2Okc,OjdzM{GwOlY9N2F-
Antiproliferative assay	Ml;rV3VRNU1{		NWLsdo5xPzJiaILz		Mlz4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVVWCtUVIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRk9ES0tvODDhd5NigSxiSVO1NEA:KDBwMUGyJO69VS5?	NVH3[4huRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN\|ExPjZpPkK3NVMyODZ4PD;hQi=>
Antiproliferative assay	NH3oeYZUXS2GSFyx		M3rufFczKGi{cx?=		NXfoc2toSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTWU1FUExzIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJxQ1PLMVgh[XO\|YYmsJGlEPTBiPTCwMlE{PiEQvF2u	NX60OpBoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN\|ExPjZpPkK3NVMyODZ4PD;hQi=>
Antiproliferative assay	NXfsWodkVkOLLVizNVIz		M364cVczKGi{cx?=		MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IN\|EzOiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDN0OFSz24JIF{e2G7LDDJR\|UxKD1iMD6yNUDPxE1w	NVi1OnV1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN\|ExPjZpPkK3NVMyODZ4PD;hQi=>
Function assay	M2fWR25EUS2KM{GyNi=>		NF\jTWM4OiCqcoO=		MnXtTY5pcWKrdHnvckBw\iCDTFug[ZhxemW\|c3XkJIlvKGi3bXHuJG5EUS2KM{GyNkBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKvR2NMNThiYYPzZZktKEmFNUCgQUAxNjJ4MTFOwG0v	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MUC2Okc,OjdzM{GwOlY9N2F-
Antiproliferative assay	MoXUUmlJNzOWMx?=		Mnr4O\|IhcHK\|		MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKE6LSD:zWFMh[2WubIOg[ZhxemW\|c3nu[{B4cWymIIT5dIUhTU2OND3BUGsh[W[2ZYKgO\|IhcHK\|IHL5JHNTSi:FQ1utPEBie3OjeTygTWM2OCB;IECuNlg{KM7:TT6=	M1jO[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
Antiproliferative assay	NW[xN3JiVkmKL{PUNy=>		MoPJO\|IhcHK\|		MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKE6LSD:zWFMh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BNOTF7NjDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KFOUQj;DR2suQCCjc4PhfUwhUUN3MDC9JFEvOTZizszNMi=>	NYO1OpR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN\|ExPjZpPkK3NVMyODZ4PD;hQi=>
Antiproliferative assay	M{jTXWFNUy2yb4PpeIl3\SCNQWLQRXMzQTl?		M1TLW\|czKGi{cx?=		MlnSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDTFutdI9{cXSrdnWgT2FTWEGVMkm5JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBu\WG\|dYLl[EBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyJFk3KGGzdXXveZMhd26nIIPvcJV1cW:wIHPlcIwheHKxbHnm[ZJifGmxbjDhd5NigSxiSVO1NEA:KDBwM{[1JO69VS5?	M1K4Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUS0PFMyLz5{N{G0OFg{OTxxYU6=
Antiproliferative assay	MkC2RWxMNW6nZ3H0bZZmKFV7M{e=		NHPiV484OiCqcoO=		M4XYdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQVzLMY5m\2G2aY\lJHU6OzdiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJiOU[gZZF2\W:3czDvcoUhe2:udYTpc44h[2WubDDwdo9tcW[ncnH0bY9vKGG\|c3H5MEBKSzVyIE2gNk4zQDZizszNMi=>	M{HXSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUS0PFMyLz5{N{G0OFg{OTxxYU6=
Cytotoxicity assay	M37DbWhmeEd{		MUS3NkBpenN?		M17lOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB\|Lkeg{txONg>?	NHP0fHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O5OlkzQSd-MkezPVY6Ojl:L3G+
Cytotoxicity assay	NY\Hc4tVVUmDUHHDZVI>		NEPpPZc4OiCqcoO=		NH7rRnlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOUUGSYVPhNkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gO{4yPiEQvF2u	NV3PUYIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezPVY6OjlpPkK3N\|k3QTJ7PD;hQi=>
Cytotoxicity assay	NGnqe4dJS0N6Mke=		NFfRTG44OiCqcoO=		MkTvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNEQDJ5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB5LkK1JO69VS5?	M1rIVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{m2PVI6Lz5{N{O5OlkzQTxxYU6=
Cytotoxicity assay	NUezflZxU0GUUFHTNlk6		NVjWXIk1PzJiaILz		NXLEOIFTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0GUUFHTNlk6KGOnbHzzJIhiemKxcnnu[{BPWE1vQVzLJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFY5KM7:TT6=	NXzrZ2c{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0O\|Q6OjVpPkK3OFc1QTJ3PD;hQi=>
Cytotoxicity assay	NIj2TI1JS0N5OB?=		MkTXO\|IhcHK\|		MnTKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNEPzhiY3XscJMhcGG{Yn;ybY5oKFOOQ{O0RVIuWk:VMTDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkO0JO69VS5?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR5NEmyOUc,Ojd2N{S5NlU9N2F-
Antiproliferative assay	MlrVV3UuTEiOMR?=		NH;Dcok4OiCqcoO=		NX7m[WJjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBCVEtiY3;ud5RqfHW2aY\lcJkh[WO2aY\heIVlKGi3bXHuJHNWNUSKTEGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDvdkBES0t6IHHzd4F6NCCLQ{WwJF0hOC5yOUKzJO69VS5?	MnOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5Nkm2NlMoRjJ5N{[5OlI{RC:jPh?=
Antiproliferative assay	M{nrd25EUS2KM{GyNi=>		MWm3NkBpenN?		NEHhcmtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGFNUyClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhcHWvYX6gUmNKNUh\|MUKyJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwMUCwPUDPxE1w	NW\rbpRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3Olk3OjNpPkK3O\|Y6PjJ\|PD;hQi=>
Antiproliferative assay	NUTKXnZWU0GUUFHTNlk6		MXO3NkBpenN?		NYn0UZlbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBCVEtiY3;ud5RqfHW2aY\lcJkh[WO2aY\heIVlKGi3bXHuJGtCWlCDU{K5PUBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJI9zKEOFS{igZZN{[XluIFnDOVAhRSByLkGwOFkh\|ryPLh?=	NVjI[G1TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3Olk3OjNpPkK3O\|Y6PjJ\|PD;hQi=>
Function assay	NXnvTFJ6VkmKL{PUNy=>				NGPoVIZKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBPUUhxM2SzJINmdGy\|LDDJR\|UxKD1iMD6wPEDPxE1w	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	MXzOTWgwO1R\|				Mn3jTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gUmlJNzOWMzDj[YxteyxiSVO1NEA:KDBwMEig{txONg>?	NIHpSWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	NE\pTZlPUUhxM2Sz				MX7Jcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyCIMUG3OGwhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKE6LSD:zWFMh[2WubIOsJGlEPTBiPTCwMlE3PSEQvF2u	NHL6VWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	MmDEUmlJNzOWMx?=				M4XMTmlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIF[xNVc1VCCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFAvOTZ3IN88UU4>	NUPtVXJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PDBpPkK4OFMyOzRyPD;hQi=>
Function assay	Ml7EUmlJNzOWMx?=				NXyzc3ZPUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugR\|EyPT[\IH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R\|IHPlcIx{NCCLQ{WwJF0hOC52N{ig{txONg>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	NIjNfYZPUUhxM2Sz				M{P0bGlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIFOxNVU3YSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFAvPDd6IN88UU4>	M4nyWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Function assay	MmjoUmlJNzOWMx?=				NGjH[3pKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDHNVI3QUFibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjZyNTFOwG0v	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	MYTOTWgwO1R\|				MlXiTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiR{GyOllCKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNE43ODVizszNMi=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	NHu5VXpPUUhxM2Sz				MnO2TY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiU{GyNFZ[KG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNE43OjZizszNMi=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	M3HsTG5KUC9\|VEO=				NGO1e4ZKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDTNVIxPllibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjZ{NjFOwG0v	NGHEcYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	M4i0[G5KUC9\|VEO=				NYr1ToxUUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugUFEyQT[PIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R\|IHPlcIx{NCCLQ{WwJF0hOC56NEOg{txONg>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	NWXa[ppCVkmKL{PUNy=>				MmrDTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiTEGxPVZOKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNE45PDNizszNMi=>	NGOxPFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	NW\UWYZnVkmKL{PUNy=>				NXS2cYdkUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugUFEyPTKUIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R\|IHPlcIx{NCCLQ{WwJF0hOS5yMk[g{txONg>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	NYTwcHNMVkmKL{PUNy=>				MkXBTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiTEGxOVJTKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNU4xOjZizszNMi=>	NH;Ed\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	MUXOTWgwO1R\|				Mof4TY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiR{GyNFJTKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNU4yPDhizszNMi=>	NVO4NY1WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PDBpPkK4OFMyOzRyPD;hQi=>
Function assay	M4HObG5KUC9\|VEO=				M{OzVGlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIFexNlAzWiCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFEvOTR6IN88UU4>	NFPlTlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	MkDVUmlJNzOWMx?=				MWDJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyBzMUWxWIlveyCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFMvODN7IN88UU4>	MkHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN\|QxRC:jPh?=
Function assay	Mm\6UmlJNzOWMx?=				NInxXXFKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzCxNVUyXGmwczDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gUmlJNzOWMzDj[YxteyxiSVO1NEA:KDNwMEO5JO69VS5?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Cytotoxicity assay	M1HFUGVDSzF?		M2T6flczKGi{cx?=		NV\OSY5jS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTUKFMTDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliQ3XscEBVcXSncj3HcI8h[XO\|YYmsJGFkfGm4aYT5JF0hOC5yMUOg{txONg>?	NW[0N4NLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OVU3OzVpPkK4O\|U2PjN3PD;hQi=>
Cytotoxicity assay	MYLNT241PQ>?		MXq3NkBpenN?		MoHIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWtPPDViY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KEOnbHygWIl1\XJvR3zvJIF{e2G7LDDBZ5Rqfmm2eTC9JFAvODJ{IN88UU4>	MlLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5NUW2N\|UoRjJ6N{W1OlM2RC:jPh?=
Cytotoxicity assay	Mli5VGM{		NEfWToI4OiCqcoO=		MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGxiVHn0[ZIuT2yxIHHzd4F6NCCDY4Tpeol1gSB;IEKuNlQ1KM7:TT6=	NXvWXHg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OVU3OzVpPkK4O\|U2PjN3PD;hQi=>
Function assay	M4XmNWJCTjN?		MUS3NkBpenN?		M2n3fGlvcGmkaYTpc44hd2ZiRV3MOE1nfXOnZDDBUGshMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjByMEOg{txONg>?	MlvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Function assay	MUjCRWY{		NGfrTHA4OiCqcoO=		M2DjXmlvcGmkaYTpc44hd2ZiTmDNMYZ2e2WmIFHMT{ApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSUZ\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODByMzFOwG0v	NIXpbGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Function assay	M17MSWJCTjN?		Mmf3O\|IhcHK\|		NETmZXlKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDBUGshMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjByMEOg{txONg>?	Ml;0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Antiproliferative assay	NH;vN\|NPS0lvSEOxNlI>		NXTOZnVuPzJiaILz		M1HyZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCHTVy0MYZ2e2WmIFHMT{B3[XKrYX6xJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xOzdizszNMi=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Antiproliferative assay	NUDTWJpvVkOLLViyNlI5		MYi3NkBpenN?		NFzyOmdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOjJ{ODDj[YxteyCqYYLic5JqdmdiRV3MOE1nfXOnZDDBUGshfmG{aXHuN{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODd\|IN88UU4>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Function assay	M3vuOmJCTjN?		NGTzcVE4OiCqcoO=		NH:5WIxKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDBUGshSzFzNU\ZJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuNVUh\|ryPLh?=	MknYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Function assay	NF[0[XVDSUZ\|		NHL3Wm04OiCqcoO=		M4Oze2lvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigRWxMKEZzMUe0UEBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlMzKM7:TT6=	NGHtR\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Function assay	NGjSOmlDSUZ\|		M{XjSFczKGi{cx?=		MY\Jcohq[mm2aX;uJI9nKFSHTD3meZNm\CCDTFugS\|EzODKUIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwNEOg{txONg>?	MmjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Antiproliferative assay	M1LQTGNJVA>?		MVK3NkBpenN?		MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFPIUEBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuOFUh\|ryPLh?=	MnP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Function assay	NFXVW5JDSUZ\|		NIns[\|U4OiCqcoO=		MojsTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiQVzLJGwyOTl4TTDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQlHGN{Bk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkW5JO69VS5?	NEfCe3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Antiproliferative assay	NIfJZoJDSUZ\|		Mn;SO\|IhcHK\|		NFfEc49CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCxMlEh\|ryPLh?=	MlTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Antiproliferative assay	MlnWR2hQ		MmnVO\|IhcHK\|		MknMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDDTG8h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCzMlIh\|ryPLh?=	NEDMZ3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Antiproliferative assay	NGPNZmdPS0lvSEKyNlg>		MkXCO\|IhcHK\|		NGOybXdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOjJ{ODDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOi53IN88UU4>	M3LYZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MEmxOFI2Lz5{OUC5NVQzPTxxYU6=
Antiproliferative assay	MkPuTFIzOjhxQ2K=		MVe3NkBpenN?		MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEh{MkK4M2NTKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxNEDPxE1w	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB7MUSyOUc,OjlyOUG0NlU9N2F-
Function assay	MVjINlIzQA>?	MkPiNE42KHWP	MVKzJIhzew>?		MlL6TY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gTFIzOjhiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gRWtVKHCqb4PwbI9zgWyjdHnvckBifCByLkWgeW0h[W[2ZYKgN{BpenNiYomgW4V{fGW{bjDicI91KG2ndHjv[C=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB7MUSyOUc,OjlyOUG0NlU9N2F-
Function assay	NXn5SI03SmFxRkO=	NWrBdFg3OC5zIITvJFEhfU1?	MYK3NkBpenN?		M2HjTGlvcGmkaYTpc44hd2ZiaIXtZY4hf2muZDD0fZBmKEWPTESg[pV{\WRiQVzLJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBk\WyuIIDyc4xq\mW{YYTpc44h[XRiMD6xJJRwKDFidV2gdJJmcW6ldXLheIVlKG[xcjC3NkBpenNiZn;scI94\WRiYomgcYV1cHmuLUPIMZRpgW2rZHnu[UBqdmOxcoDvdoF1cW:wIH3lZZN2emWmIHHmeIVzKDhiaILzJIJ6KG[rbITldkB{[2mwdHnscIF1cW:wIHPveY51\Q>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB7MUSyOUc,OjlyOUG0NlU9N2F-
Antiproliferative assay	M1HmR2tCWlCDU{K5PS=>		M{Hoc\|czKGi{cx?=		NH7U[GZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvBVnBCWzJ7OTDj[YxteyCqYYLic5JqdmdiTmDNMWFNUyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yOEeg{txONg>?	MoPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{S4NFkoRjJ7MUe0PFA6RC:jPh?=
Antiproliferative assay	NF[y[Y9JS0N5OB?=		Mor6O\|IhcHK\|		MlLCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ1O3PEBk\WyuczDoZZJjd3KrbnegV2xEOzSDMj3SU3MyKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjF5IN88UU4>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5NEiwPUc,OjlzN{S4NFk9N2F-
Antiproliferative assay	NY\NPWdQVkOLLViyNlI5		NHPCTWk4OiCqcoO=		NFr0S3FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOjJ{ODDj[YxteyCqYYLic5JqdmdiRV3MOE1CVEtiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMkSg{txONg>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5NEiwPUc,OjlzN{S4NFk9N2F-
Antiproliferative assay	M3fNe25EUS2KM{GyNi=>		Mo\lOFghcHK\|		MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IN\|EzOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE45KM7:TT6=	NIrMTHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3OFgyPCd-MkmxO\|Q5OTR:L3G+
Antiproliferative assay	MWfIR2M4QA>?		Ml7sOFghcHK\|		NHP6[GVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR\|c5KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyJO69VS5?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5NEixOEc,OjlzN{S4NVQ9N2F-
Antiproliferative assay	NH3GUWVGSkNz		M4nOO\|czKGi{cx?=		M1P1W2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRVLDNUBk\WyuczDh[pRmeiB5MjDodpMh[nliQXzhcYFz[my3ZTDhd5NigSxiSVO1NEA:KDBwMEGzJO69VS5?	NU\GVFBkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNFI1OTBpPkK5NlAzPDFyPD;hQi=>
Antiproliferative assay	MUHNT241PQ>?		MVG3NkBpenN?		MlzIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPS160OUBk\WyuczDh[pRmeiB5MjDodpMh[nliQXzhcYFz[my3ZTDhd5NigSxiSVO1NEA:KDBwMEKyJO69VS5?	NGq0SpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlQyOCd-MkmyNFI1OTB:L3G+
Antiproliferative assay	MmnSUWNHPw>?		MVW3NkBpenN?		NXjtdIFUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XKkbIXlJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3ysJGlEPTBiPTCwMlA1PSEQvF2u	NHjLXVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlQyOCd-MkmyNFI1OTB:L3G+
Antiproliferative assay	M{POTGE2PDl?		MWW3NkBpenN?		MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEGuYX3hdoJtfWViYYPzZZkhemWuYYTpeoUhfG9iY3;ueJJwdCxiSVO1NEA:KDBwMUO0N{DPxE1w	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkSxNEc,Ojl{MEK0NVA9N2F-
Antiproliferative assay	M175eGhEXDFzNh?=		MV23NkBpenN?		MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliQXzhcYFz[my3ZTDhd5NigSC{ZXzheIl3\SC2bzDjc451em:uLDDJR\|UxKD1iMD6yOVM3KM7:TT6=	M3nvcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyOFExLz5{OUKwNlQyODxxYU6=
Antiproliferative assay	MWXTS2M4QTBz		NXLnRo5WPzJiaILz		NEizOVdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPHR\|c6ODFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGFt[W2jcnLseYUh[XO\|YYmgdoVt[XSrdnWgeI8h[2:wdILvcEwhUUN3MDC9JFAvOzJzMzFOwG0v	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkSxNEc,Ojl{MEK0NVA9N2F-
Antiproliferative assay	MmLIUmNKNUh2NkC=		NEfZR2o4OiCqcoO=		NHrhcHhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBCdGGvYYLicJVmKGG\|c3H5MEBKSzVyIE2gNk4zPDRizszNMi=>	NUPuSIh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNFI1OTBpPkK5NlAzPDFyPD;hQi=>
Antiproliferative assay	MUTDU2xQOjB3		MV23NkBpenN?		NEPrfW1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPPUG8zODViY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGFt[W2jcnLseYUh[XO\|YYmsJGlEPTBiPTCyMlQ1QSEQvF2u	M3O3WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyOFExLz5{OUKwNlQyODxxYU6=
Antiproliferative assay	NITTVIhRSzN?		MYK3NkBpenN?		M1\YVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCDbHHtZZJjdHWnIHHzd4F6NCCLQ{WwJF0hQS55OEeg{txONg>?	NUDRUY1PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNFI1OTBpPkK5NlAzPDFyPD;hQi=>
Antiproliferative assay	NEPKfIRDSUZ\|		NFjJNFk4OiCqcoO=		NEmyXFJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGNFPzRvUl;TNUBi\nSncjC3NkBpenNiYomgV3JDKG:{IFPDT\|gh[XO\|YYmsJGlEPTBiPTCwMlA1QDZizszNMi=>	NHfXd289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Antiproliferative assay	NIPENlZDSUZ\|		NHe5cpY4OiCqcoO=		MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwMEW3OUDPxE1w	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
Antiproliferative assay	NVzscZZGW1VvRFjMNS=>		MmrmO\|IhcHK\|		Mle4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVVT3ETGwyKGOnbHzzJIhiemKxcnnu[{BPWE1vQVzLJIFnfGW{IEeyJIhzeyCkeTDTVmIhd3JiQ1PLPEBie3OjeTygTWM2OCB;IECuNVU2KM7:TT6=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
Antiproliferative assay	NXz0dVNFU0GUUFHTNlk6		NEfFbWs4OiCqcoO=		NWrubZpvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiaHHyZo9zcW6pIF7QUU1CVEtiYX\0[ZIhPzJiaILzJIJ6KFOUQjDvdkBES0t6IHHzd4F6NCCLQ{WwJF0hOC5zN{[g{txONg>?	NV24bFZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
Antiproliferative assay	MX;OR2kuUDNzMkK=		NEn4OXo4OiCqcoO=		NGG1SWdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOzF{MjDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjNyMzFOwG0v	NYfEVFhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
Antiproliferative assay	NUH0d3pDSkGIMx?=		M{[w[lczKGi{cx?=		NV62NVRUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BGVUx2LVHMT{BNOTF7Nl2gcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwM{Sg{txONg>?	NHP1WGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Antiproliferative assay	NXzCc\|NpSkGIMx?=		NWjwXJBuPzJiaILz		MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNIFexNlAzWiCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCxcjDDR2s5KGG\|c3H5MEBKSzVyIE2gNE42PjRizszNMi=>	M2fWc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
Antiproliferative assay	NWnjPYV4SkGIMx?=		NFT5W3M4OiCqcoO=		M{nEV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegR2Q4PC2UT2OxJGczODN{UjDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KFOUQjDvdkBES0t6IHHzd4F6NCCLQ{WwJF0hOC53OUSg{txONg>?	M{XUc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
Antiproliferative assay	Mo\qRmFHOw>?		NIS2Z4U4OiCqcoO=		NFPDfVVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGlNOy2\|dHnteYxifGWmIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDvdkBES0t6IHHzd4F6NCCLQ{WwJF0hOC54NESg{txONg>?	MkXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
Antiproliferative assay	MnjmTGNEPzh?		MYe3NkBpenN?		NFXRZXhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR\|c5KGOnbHzzJIhiemKxcnnu[{BUVEN\|NFGyMXJQWzFiYX\0[ZIhPzJiaILzJIJ6KFOUQjDvdkBES0t6IHHzd4F6NCCLQ{WwJF0hOC56OEmg{txONg>?	NXXEVVhNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
qHTS assay	NWfafJU1XEN\|Mh?=				NETjUFRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	M2X4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NUjPO\|VISTZ5Mx?=				NFPCXppyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	NVe1folERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	MnmwV4Fwey1{				M{XiRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	NH\ZU2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	NH;IO2dTTA>?				M4jiZZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	NYr4fG9JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	MX;TT{1PNVOK				NIH3N4tyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	NHXCXJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	MWDCWE0yOg>?				MWXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NHjGV4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	MWPNS{A3OyBqNj3US{BTMQ>?				MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	NGHZOmJPSjF4NEO=				NXvJO2xreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	M{nSOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	MVPPTHMuPTB?				MlHPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	NVXBSlFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	M3zjZ2xCVi13				M1fkPJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGxCVi13IHPlcIx{	MmLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	MlXWUmIuTUKlMR?=				MmPodWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	M1XlXnNMNU5vU1i=				M1fYXZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN?	M3z6ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	M3LCOnJpPDF?				NFfRTohyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	M{PRemE3PzN?				NUOzPWl{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	MkX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	M{HrPHJpOzB?				M4roSpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	NIfmfnNDXC1\|Nx?=				Mo\hdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOzdiY3XscJM>	NE\PUmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	MkTxUWchPjNiKE[tWGchWil?				M3HT[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG1IKDZ\|IDi2MXRIKFJrIHPlcIx{	NVyyfYNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	NHj1WndTcDNy				MoDidWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	M{\NTm9JWy13MB?=				NX\KbndOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	NF;QemE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	NHzLXWZUUi2JQl2y				MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NILFNYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	NHW2R\|lUUy2QLV3D				M1TkTZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	NH3IWI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	NILi[nNPSi2HQnOx				NEnZfFByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	MkLMUGFPNTV?				M1;iRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	M2K5eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	M37FfXJpOTh?				NYPpeJJkeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	MoTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NYq3[2tDVkJzNkSz				MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORlE3PDNiY3XscJM>	NFrlOlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	M2DCR3NMNU5vTVO=				M2jIb5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN?	MlXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NF25TlVVSzN{				M4W1fpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	M3jMS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NHvQTZRTcDF6				NEDPSFFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDF6IHPlcIx{	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	MXjTZY9{NTJ?				M4DOT5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNid3NvMjDj[Yxtew>?	M2HkVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Antiproliferative assay	MlmxSWJEOQ>?		MVe3NkBpenN?		MoLlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCHQlOxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsJHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IECuNFM6KM7:TT6=	MoPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4MEKwN\|YoRjJ7NkCyNFM3RC:jPh?=
Function assay	NYDNc2JFUHN3N{jU	MV:xNFAhdk1?	M4XVdVMxKG2rboO=		M2TLOWlvcGmkaYTpc44hd2ZiaHXwd4lvNW2nZHnheIVlKGOxbo\ldpNqd25ib3[gVJJwNUiJRjDpcpRwKGGldHn2[UBnd3KvIHnuJIh2dWGwIFjzOVc5XCClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDNSXQheGixc4Doc5J6dGG2aX;uJIF1KDFyMDDuUUBxemWrbnP1ZoF1\WRiZn;yJFMxKG2rboOg[o9tdG:5ZXSgZpkhemWlb33ibY5idnRiaIXtZY4heHKxLVjHSkBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjCzNEBucW6\|IHL5JIludXWwb3Lsc5QhdQ>?	MkO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5MEG5OlIoRjJ7N{CxPVYzRC:jPh?=
Function assay	NEfwdFFJS0NzOUO3	MVexNFAhdk1?	NILlTWo{OCCvaX7z		NEnlcmVKdmirYnn0bY9vKG:oIHjldJNqdi2vZXTpZZRm\CClb372[ZJ{cW:wIH;mJHBzdy2KR1[gbY51dyCjY4TpeoUh\m:{bTDpckBpfW2jbjDIR2MyQTN5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJG1GXCCyaH;zdIhwenmuYYTpc44h[XRiMUCwJI5OKHC{ZXnuZ5Vj[XSnZDDmc5IhOzBibXnud{Bnd2yub4fl[EBjgSC{ZXPvcYJqdmGwdDDoeY1idiCycn:tTGdHKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFMxKG2rboOgZpkhcW2vdX7vZoxwfA>?	Mlv5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5MEG5OlIoRjJ7N{CxPVYzRC:jPh?=
Antiproliferative assay	MmPaUmNKNUh{MkK4		NVnMc\|NJPzJiaILz		NELKTHpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOjJ{ODDj[YxteyCqYYLic5JqdmdiRV3MOE1CVEtiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEi3JO69VS5?	NVv2UXc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNlMyOjBpPkOwNlI{OTJyPD;hQi=>
Antiproliferative assay	M1vaV2hESzd6		NFOwXXQ4OiCqcoO=		M3Hs[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPDO\|gh[2WubIOgbIFz[m:{aX7nJHNNSzN2QUKtVm9UOSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zNzFOwG0v	NXjWeXJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNlMyOjBpPkOwNlI{OTJyPD;hQi=>
Antiproliferative assay	MVLLRXJRSVN{OUm=		NVjwbYhDPzJiaILz		M2nsemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1HSVGFUOjl7IHPlcIx{KGijcnLvdolv\yCQUF2tRWxMKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjJ2IN88UU4>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ{M{GyNEc,OzB{MkOxNlA9N2F-
NB1	NXXZUmpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DDO2lEPTB;OUGuPVghdk1?	NXS5SGhSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NCI-SNU-5	MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF:2XHpKSzVyPUGwOU44PSCwTR?=	NYLRdnNbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SR	M4r0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTF{Nj6zNUBvVQ>?	NHfTNII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
SF539	NFHtTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HoXmlEPTB;MkC0MlI1KG6P	M2SzdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SU-DHL-1	M3;uZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTN\|Nj64NkBvVQ>?	NV7ucoN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SCC-3	NFHBOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nw[GlEPTB;M{W2Mlc3KG6P	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
DEL	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjPTWM2OD1\|NkmuPUBvVQ>?	Ml3qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
CTV-1	NXrqdIlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTV7Nj60PEBvVQ>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
EM-2	MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\ScmVlUUN3ME22NFEvOzRibl2=	M33VOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
MHH-CALL-2	M1PJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moq5TWM2OD14OEKuOVchdk1?	MorvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KM12	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfRbHJKSzVyPUewOk46KG6P	NGm2UW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
KINGS-1	NIjhVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTtdJJKSzVyPUe0PU44PSCwTR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
MEG-01	MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmC3TWM2OD16NUeuOlYhdk1?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
BV-173	MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHj0Z\|NKSzVyPUGuNFU6QTdizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
LAMA-84	M2\jcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfwdY5KSzVyPUGuN\|gzQDJizszN	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
KARPAS-299	NHjPSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfMTWM2OD1zLkSwPFYyKM7:TR?=	NXLWcZZ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
K-562	MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHiTWM2OD1zLkeyNlY6KM7:TR?=	M{fWT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SK-LMS-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF21TpFKSzVyPUGuO\|Y5PjdizszN	MmD2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
MOLT-16	NYL5UGdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\nS2lEPTB;MT65OVU4PSEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CMK	M37yWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTFwOU[xOVkh\|ryP	NGDQWIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
ST486	M3fBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nsdWlEPTB;Mj60N\|A4OyEQvF2=	NYK1bppyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
CI-1	NYjYeplnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPLTWM2OD1{LkS5OlU6KM7:TR?=	NV\VOXBtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
KP-N-RT-BM-1	NXnEW49iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\pTWM2OD1{LkewNVIzKM7:TR?=	M2f3ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
ALL-PO	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4e1W2lEPTB;Mz6xPFIxPyEQvF2=	M{PCSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
KS-1	MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELJNHNKSzVyPUOuNlEzOjVizszN	NFq1bFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
Becker	NH[4TpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3foRWlEPTB;ND6yN\|k{KM7:TR?=	MkS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
GDM-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTRwMkS2NVch\|ryP	M2q5fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
BC-1	NYrh[mlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlP1TWM2OD12LkS5Nlc4KM7:TR?=	MnXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NB14	Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTRwOEO1NlQh\|ryP	NWDzNodZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NOS-1	NYHKWoYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnDTlBKSzVyPUWuN\|M5PzRizszN	NEXyT2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
MZ1-PC	NFKxdXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTHTWM2OD13LkiyNVUyKM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
A498	NVfyeVl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;NTWt7UUN3ME22MlA5PDd\|IN88US=>	NXriVVIyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
EW-16	NUW4dVV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTZwM{e3O\|Mh\|ryP	M3rKOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NALM-6	NVjiUVA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTZwNkizPFch\|ryP	NGDqd209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
EB-3	NIrRRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\rVGhKSzVyPUeuNFczOzNizszN	M3fUOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
697	MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFztfIlKSzVyPUmuNlQ{OjlizszN	MlL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10	NGLEfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nLZ2lEPTB;OT61PVg1OiEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
KNS-81-FD	MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTlwNkm2OVMh\|ryP	NXXxeXFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
HUTU-80	NEnDSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTlwN{S2OFIh\|ryP	NELzdpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
LS-411N	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTmeGNlUUN3ME2xNE4xPTZ5IN88US=>	M3rwb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
RPMI-8402	NWW1OpJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGri[VlKSzVyPUGwMlEyPiEQvF2=	NXzJTIJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
KU812	M1ezeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTFyLkK5PVEh\|ryP	NWPuXFJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
EW-1	NWHQWnZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzTTWM2OD1zMD60OFI2KM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
HC-1	NED0ZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1[3NmlEPTB;MUCuOFg1PCEQvF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NB69	M4rWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7jOYlPUUN3ME2xNE42ODR\|IN88US=>	NGPaeGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
MFH-ino	Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHrWbJpKSzVyPUGwMlg{ODNizszN	MljYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
CCRF-CEM	NEXZbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXOTWM2OD1zMT61PVch\|ryP	NWLGT3VIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SK-N-DZ	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrLe3ZwUUN3ME2xNk4xPDN4IN88US=>	MknQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NCI-H720	NWLzV21IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHZTWM2OD1zMj6xO\|A2KM7:TR?=	MonkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
HCC1187	MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3weI5KSzVyPUGyMlIxPDFizszN	M4LZUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
IST-SL2	MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPzTWM2OD1zMj60PFczKM7:TR?=	M2\Fb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
KE-37	MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnMeVdRUUN3ME2xNk44QTZ4IN88US=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
HCC1599	M17tTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1j3SmlEPTB;MUKuPVA3QSEQvF2=	NIXjOHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
A4-Fuk	MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnkTWM2OD1zMj65OVg3KM7:TR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NKM-1	NGn0S25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33C[GlEPTB;MUOuNlkzPSEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
BE-13	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTF\|Lke5PFkh\|ryP	NET0fZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
MV-4-11	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrSU3ZKSzVyPUG0MlA{OjRizszN	NGDkVWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
OPM-2	NVnqXoVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrSTWM2OD1zND60NFg2KM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
KARPAS-422	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTF2LkWxNlYh\|ryP	NGPR[Yg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
RPMI-8226	MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojkTWM2OD1zND64PVE2KM7:TR?=	NGTpRm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
KARPAS-45	Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjmO3RKSzVyPUG1Mlc4OTZizszN	M3;tXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SK-PN-DW	NWr4NGNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXNPWlKSzVyPUG1Mlg3OzFizszN	MmG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
LC-2	NEXsUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XNfGlEPTB;MU[uNVUxPiEQvF2=	M2rHXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NCI-H1648	NH;rfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTF4LkK1OEDPxE1?	M33POFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
RL95-2	MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWC1Z2FyUUN3ME2xOk4{QTd6IN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
KNS-42	NUD5RXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TzRmlEPTB;MU[uO\|I4PCEQvF2=	Mme5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
RPMI-6666	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\U[XlQUUN3ME2xOk46OjFzIN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SIG-M5	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFf2ZllKSzVyPUG3MlE6ODNizszN	NVfp[VRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
VA-ES-BJ	NUO1[FF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvETWM2OD1zNz63OFUyKM7:TR?=	M4P4Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
MONO-MAC-6	MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XOdmlEPTB;MUeuPVMyOiEQvF2=	M372OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LAN-6	NWnEbmdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTF6Lke1OVch\|ryP	NUHSR4NDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
A388	NHnDSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfFV5FQUUN3ME2xPU4{ODV7IN88US=>	NIX6RmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
SK-NEP-1	M1TFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTJyLkKxN\|Ih\|ryP	M3m0cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
TE-10	M3jpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HtVmlEPTB;MkCuOVIzOSEQvF2=	M{j5flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
HL-60	M3rtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvFT3FoUUN3ME2yNE46ODl7IN88US=>	NVuxcZFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
MC116	NUnmN2ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTJzLkeyNlEh\|ryP	NWDrdm52RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SW962	NV7rTGU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXwTWM2OD1{MT63PVE2KM7:TR?=	NFzJNI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NOMO-1	Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTJ{Lk[1OlQh\|ryP	MmS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
CTB-1	NH\qdGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M363e2lEPTB;MkKuPFY4OSEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
MRK-nu-1	NUfQVmQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTJ{LkmwO\|Qh\|ryP	NGK5RVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
GR-ST	MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnDO5BKSzVyPUKzMlc3KM7:TR?=	Mo\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
HH	M2\Rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXraZlBMUUN3ME2yOE4xODNizszN	NHrOZoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NCI-H1963	M2fSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLscJp3UUN3ME2yOE4xPzh{IN88US=>	NIXLbZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
QIMR-WIL	M2TjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHKySWVKSzVyPUK0Mlg4PzJizszN	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CGTH-W-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\6XJhKSzVyPUK1MlA4OjNizszN	M2nsWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LP-1	NXHnemZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4[4XmlEPTB;MkWuOlU2OSEQvF2=	NIXXemw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NCI-H748	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXTTWM2OD1{Nj61NVM4KM7:TR?=	NUPteZVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
PF-382	NIDyT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDOfG1KSzVyPUK3MlIzOjNizszN	MoT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
ATN-1	MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHZTWM2OD1{Nz6zO\|MzKM7:TR?=	NUXxR2dHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
L-540	M3yzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DQe2lEPTB;MkeuOlQ2QSEQvF2=	M1;GelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LXF-289	M2LiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTJ5Lke1NVkh\|ryP	MlSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
LS-513	MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTJ6LkG4NFch\|ryP	NIm0eI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NCI-H1581	NGDUdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFKyXGtKSzVyPUOwMlM6PzZizszN	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
ES6	NIfM[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1u3TmlEPTB;M{CuOlg6QSEQvF2=	M2jGXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SW982	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXBTWM2OD1\|MD64OVY3KM7:TR?=	Mn31QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
DOHH-2	MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrvblZZUUN3ME2zNU42QDl\|IN88US=>	M2G3S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
DB	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXKboRKSzVyPUOzMlk1OzFizszN	M4rINVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
MPP-89	NHv6d3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXrS\|BKSzVyPUO0MlE4PTZizszN	MnjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
LB831-BLC	NFPMWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn2yTWM2OD1\|ND61NVg1KM7:TR?=	M{i0Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NB5	NEHQOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULQV5RqUUN3ME2zOE45PTN3IN88US=>	NVHHS495RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
GB-1	M3f2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2S1V2lEPTB;M{WuNFQ3QSEQvF2=	NUf5NXVORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
TE-15	MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mki5TWM2OD1\|NT6yNlM5KM7:TR?=	Ml;RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
LC4-1	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTFTWM2OD1\|NT6zPFQ4KM7:TR?=	NFXONIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NCI-H747	NE\xRYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zyNWlEPTB;M{[uNVM3QSEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NTERA-S-cl-D1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DCc2lEPTB;M{iuO\|M1PyEQvF2=	NXfzR4JYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SK-MM-2	NXvKeXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;w[21KSzVyPUSwMlEyPDZizszN	M4HoUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
TGW	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF63WW1KSzVyPUSxMlA2PjNizszN	NYL6R3NWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
ONS-76	NWLWVJp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HlcGlEPTB;NEKuOFg5OyEQvF2=	Moq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
CPC-N	NHyyfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTR{Lkm5O\|Eh\|ryP	M1\HUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
ES4	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTR2LkSxOVMh\|ryP	NGHoWYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
Daudi	NFvMOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknXTWM2OD12NT6wPFI4KM7:TR?=	NEDMNFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
MOLT-4	M1rwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nwTWlEPTB;NEWuNFg2OyEQvF2=	NHrKZmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
HT-144	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnEb\|RKSzVyPUS2MlczPiEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SW872	NX:4UmFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXvTWM2OD12OD6xPVM{KM7:TR?=	NVjwU4VORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
D-283MED	NGD1R\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTR6LkO1OFIh\|ryP	M2nGWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NCI-H2126	NV7uS\|d4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULwR3JIUUN3ME20PE45PDd4IN88US=>	M{LqVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NCI-SNU-16	MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUD4VG5jUUN3ME20PU4zOTR\|IN88US=>	NITJU2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
CESS	Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTLWWpKSzVyPUS5MlUxQDhizszN	M2\DOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
A101D	NYLifYZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fZRmlEPTB;NEmuPVc{PiEQvF2=	MkfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pALK / pAKT / pERK / pS6; PubMed: 24675041 Cancer Discov H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins. pROS1 / ROS1; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. pSTAT3 / STAT3; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. PARP / cleaved caspase-3 / Bax / Bcl-2; PubMed: 25193856 Oncotarget The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr. p-c-Met / c-Met; PubMed: 25193856 Oncotarget Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification). p-mTOR; PubMed: 26384345 Oncotarget Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.	24675041 25351743 25193856 26384345
Immunofluorescence	LC3 / lysosome; PubMed: 26384345 Oncotarget Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. SRC / Met; PubMed: 26517812 Oncotarget Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. α-tubulin; PubMed: 26517812 Oncotarget LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm. cytochrome c; PubMed: 25193856 Oncotarget PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red p-ALK; PubMed: 25193856 Oncotarget PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.	26384345 26517812 25193856

体内研究

PF-2341066每天按50 mg/kg和75 mg/kg剂量处理GTL-16 模型, 引起大肿瘤 (体积大于600 mm³) 明显衰退，且按43天处理日程处理后，平均肿瘤体积降低60%。在另一项研究中, PF-2341066处理3个月以上，完全抑制GTL-16肿瘤生长，PF-2341066每天按50 mg/kg剂量处理小鼠，3个月后，只有1/12小鼠的肿瘤生长得到提高。PF-2341066每天按50 mg/kg剂量处理NCI-H441 NSCLC 模型处理周期为38天，观察到平均肿瘤体积降低43%。PF-2341066 每天按50 mg/kg剂量作用于 Caki-1 RCC模型，处理周期为33天，观察到平均肿瘤体积降低53%，且每种肿瘤体积降低至少30%。PF-2341066每天按 50 mg/kg剂量作用于 U87MG 恶性胶质瘤或PC-3前列腺癌移植瘤模型,几乎完全抑制肿瘤生长，在实验最后一天，抑制分别达97% 或84%。相反, PF-2341066每天按50 mg/kg剂量口服给药处理 MDA-MB-231 乳腺癌模型,或 DLD-1 结肠癌模型，不会显著抑制肿瘤生长。PF-2341066每天按12.5 mg/kg, 25 mg/kg, 和50 mg/kg剂量作用于 GTL-16 肿瘤，观察到CD31阳性内皮细胞显著降低，这种作用存在剂量依赖性，说明 MVD 受抑制，且具有相关的抗癌高效性，这种作用也存在剂量依赖性。PF-2341066 作用于GTL-16 和 U87MG 模型，显著降低人VEGFA 和IL-8血浆水平，这种作用存在剂量依赖性。PF-2341066口服处理GTL-16 肿瘤，观察到磷酸化的c-Met, Akt, Erk, PLCλ1,和 STAT5水平显著受抑制。^[1]PF-2341066 每天按100 mg/kg剂量口服处理携带Karpas299 ALCL 移植瘤的SCID Beige 小鼠，具有抗癌高效性，这种作用存在剂量依赖性，处理15天，所有肿瘤完全衰退。此外, PF-2341066抑制关键NPM-ALK信号调节器, 包括磷脂酶C-γ, 信号转导器，及转录因子3, 细胞外信号调节激酶, 和Akt的激活剂，这些与 NPM-ALK 磷酸化和功能受抑制相关。^[2] PF-2341066 抑制骨肉瘤的一些活动行为，及其肿瘤生长(例如, 增殖和存活)和转移 (例如，入侵和形成克隆)。PF-2341066口服饲喂裸鼠，抑制生长和相关的骨肉瘤裸鼠移植瘤的骨基质的形成。^[3] PF-2341066 按50 mg/kg 剂量处理 c-MET-扩增的GTL-16移植瘤，引起肿瘤衰退，这与¹⁸F-FDG 摄取的缓慢降低相关，且降低葡糖糖转运蛋白 1, GLUT-1的表达。^[4]

激酶实验： ^[1]	- 合并生化激酶实验: 使用连续耦合的分光光度测定c-Met催化活性，通过分析NADH消耗率而测定c-Met诱导的ADP产量，这种作用具有时间依赖性。在 340 nm处使用分光光度法在指定时间点测定吸光值的降低而计算NADH的消耗量。为了测定K_i值, 在含实验试剂的实验孔中加入不同浓度PF-2341066，然后在37^oC下温育10分钟。加入c-Met酶开始进行实验反应。
细胞实验： ^[1]	- 合并 Cell lines: GTL-16胃癌细胞和T47D乳腺癌细胞 Concentrations: 0 nM-256 nM Incubation Time: 1小时 Method: GTL-16胃癌细胞和T47D乳腺癌细胞接种在96孔板上，孔中含培养基，培养基中含10% 胎牛血清(FBS)，然后转移到无血清培养基中[含0.04%牛血清蛋白(BSA)]，处理 24小时。在调查配体依赖的RTK 磷酸化实验中，加入相应的生长因子，处理20分钟。细胞和 PF-2341066和/或适当配体在指定时间温育1小时，然后使用含 1 mmol/L Na₃VO₄的HBSS冲洗细胞一次,然后从细胞中获得蛋白裂解物。随后,通过夹心酶联免疫吸附试验法使用特定的捕获抗体在96孔板上测定选定蛋白激酶的磷酸化，使用特点检测抗体测定磷酸化的酪氨酸残基。抗体包被的实验板(a) 在蛋白裂解物存在时，在4^oC下过夜;(b)在溶于PBS的1% Tween-20 中冲洗7次;(c)在辣根过氧化物酶标记的抗总磷酸（PY-20）抗体（1:500）中温育20分钟;(d) 再次冲洗7次;(e)在3,3^′,5,5^′-四甲基联苯胺过氧化物酶底物中温育，开始显示反应，加入0.09 N H₂SO₄终止反应; (f)在450 nm 处使用分光光度计测定吸光度。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 携带NCI-H441,或DLD-1,或MDA-MB-231的雌性和雄性nu/nu小鼠 Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 和50 mg/kg/day Administration: 口服处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	9 mg/mL (19.98 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+dd H2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Crizotinib (PF-02341066) SDF

分子量	450.34
化学式	C₂₁H₂₂Cl₂FN₅O
CAS号	877399-52-5
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04148066	Recruiting	Diagnostic Test: ctDNA blood sample	Carcinoma Non-Small-Cell Lung	The Netherlands Cancer Institute\|Roche Pharma AG	July 17 2019	Phase 2
NCT03439215	Recruiting	Drug: Lorlatinib	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale\|Clinical Research Technology S.r.l.	June 13 2017	Phase 2
NCT02946216	Unknown status	Genetic: ctDNA analysis	Non-small Cell Lung Cancer Stage III\|Non-Small-Cell Lung Cancer Metastatic\|Adenocarcinoma of Lung\|EGFR Wildtype	First People''s Hospital of Hangzhou	November 2016	--
NCT02511184	Terminated	Drug: Crizotinib\|Drug: Pembrolizumab	ALK-positive Advanced NSCLC	Pfizer\|Merck Sharp & Dohme Corp.	October 2015	Phase 1
NCT02419287	Active not recruiting	Drug: crizotinib	Anaplastic Large Cell Lymphoma ALK-Positive	University of Milano Bicocca	April 2015	Phase 2
NCT02499614	Unknown status	Drug: Crizotinib	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale	December 2014	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?
回答：
Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

选择性强的c-Met抑制剂

PF-04217903 : C-Met-selective, IC50=4.8 nM.
活性最高的c-Met抑制剂

INCB28060 : C-Met, IC50=0.13 nM.
用于临床的c-Met抑制剂

Tivantinib (ARQ 197) : Phase III for Hepatocellular Carcinoma.
最新的c-Met抑制剂

EMD 1214063 ^New : Potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

研究领域

产品类型

定制您的化合物库

Crizotinib (PF-02341066)

客户使用Selleck生产的Crizotinib (PF-02341066)发表文献306篇：

产品安全说明书

c-Met抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Crizotinib (PF-02341066) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技术支持

常见问题及建议解决方法

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品